InflaRx N.V. Announces Annual Shareholder Meeting
Ticker: IFRX · Form: 6-K · Filed: Apr 3, 2025 · CIK: 1708688
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
InflaRx N.V. holding shareholder meeting April 24th, materials released.
AI Summary
InflaRx N.V. filed a Form 6-K on April 3, 2025, to announce its annual general meeting of shareholders scheduled for April 24, 2025. The company made certain materials available to shareholders in connection with this meeting, which are attached as exhibits to the filing.
Why It Matters
This filing informs shareholders about the upcoming annual meeting and provides them with necessary materials for participation and voting.
Risk Assessment
Risk Level: low — The filing is a routine procedural announcement regarding a shareholder meeting and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- April 3, 2025 (date) — Filing date and announcement of meeting
- April 24, 2025 (date) — Date of annual general meeting of shareholders
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report that InflaRx N.V. convened its annual general meeting of shareholders on April 3, 2025, and made certain related materials available to shareholders.
When is the annual general meeting of shareholders scheduled to be held?
The annual general meeting of shareholders is scheduled to be held on April 24, 2025.
What is included with this filing?
This filing includes a Convening Notice, Agenda, and Explanatory materials for the annual general meeting of shareholders as Exhibit 99.1.
Does InflaRx N.V. file annual reports under Form 20-F or 40-F?
InflaRx N.V. indicates that it files annual reports under cover of Form 20-F.
Where is InflaRx N.V. located?
InflaRx N.V.'s principal executive offices are located at Winzerlaer Str. 2, 07745 Jena, Germany.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 3, 2025 regarding InflaRx N.V. (IFRX).